Quoin Pharmaceuticals Ltd - QNRX Total Company Value-to-Revenue Ratio

Quoin Pharmaceuticals Ltd (QNRX) - corporate logo

The enterprise value-to-revenue ratio displayed by the GURU.Markets system helps assess the strategy of Quoin Pharmaceuticals (QNRX) in developing unique treatments for fatal genetic skin pathologies. 0.00 captures the magnitude of this parameter while the company spends working capital on pre-commercial tests. High loyalty among the staff of biochemists and dermatologists ensures success in treating rare dermatological diseases.

QNRX: Quoin Pharmaceuticals Ltd. Company Value to Revenue 11/23/2025 - 11/20/2026

Quoin Pharmaceuticals Ltd. - analytical breakdowns and key metrics (QNRX)

- cash and cash flow indicators:
Fundamental company valuation:QNRX - Quoin Pharma
Brand item of quoinpharma.com

The scale of drug development for rare dermatological pathologies under conditions of geopolitical neutrality makes the EV-to-revenue ratio a key indicator of the business's objective value. This metric compares the total market price of assets with sales volume, excluding the impact of debt load, which allows investors to assess the fundamental maturity of Quoin Pharmaceuticals (QNRX) and the stability of its market capitalization.